Login to Your Account



Financings Roundup


Wednesday, March 21, 2012
• GeoVax Labs Inc., of Atlanta, entered an agreement with institutional investors to sell shares of its Series A preferred stock, convertible into about 2.9 million shares of GeoVax common stock, at an aggregate price of approximately $2.2 million, and Series A warrants to purchase up to an aggregate of 2.9 million shares of GeoVax common stock with an exercise price of $1 per share and a term of five years. The transaction is expected to close on or about March 21.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription